Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
LÖWENSTEIN MEDICAL BELGIUM from Blégny, company number BE0765612486, closed financial year 2025 with a result of € -126,477 after tax. For that financial year LÖWENSTEIN MEDICAL BELGIUM recorded a gross margin of € 140,804 and equity of € -913,226. Compared with financial year 2024, the result moved from € -206,412 to € -126,477. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on January 16, 2026.
€ -913,226
▼ € 126,477 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -126,477
▲ 39 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1.1 million
▲ € 936,099 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -914,226.
People and assets in 2025
2.6
Average over the fiscal year, from the social balance sheet.
€ 243,530
▲ 8% vs 2024
€ 93,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 27,395
▼ 38% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.4 million
▲ 58% vs 2024
Loans from banks and other lenders, long and short.
€ 32,151
▼ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 41,013
▼ 23% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -126,939 | € -28,615 | € 41,131 | € 140,804 | ▲ 242% |
| Profit after taxes | € -321,476 | € -259,861 | € -206,412 | € -126,477 | ▲ € 79,935 |
| Equity | € -320,476 | € -580,337 | € -786,749 | € -913,226 | ▼ € 126,477 |
| Total debts | € 624,216 | € 816,426 | € 1,634,401 | € 2,488,228 | ▲ 52% |
| Cash | € 131,768 | € 48,436 | € 182,331 | € 1,118,430 | ▲ € 936,099 |
| Retained profit | € -321,476 | € -581,337 | € -787,749 | € -914,226 | ▼ € 126,477 |
| Bank debt | € 530,978 | € 780,069 | € 1,528,341 | € 2,409,862 | ▲ 58% |
| Balance sheet total | € 303,740 | € 236,089 | € 847,652 | € 1,575,002 | ▲ 86% |
| Employees (FTE) | 2.4 | - | 2.6 | 2.6 |
Key figures of LÖWENSTEIN MEDICAL BELGIUM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to LÖWENSTEIN MEDICAL BELGIUM?
What happened at LÖWENSTEIN MEDICAL BELGIUM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 126,477. Source: NBB ↗
- Johannes Wilhelmus Maria OUDE BREUIL became a director. NBB
- New establishment in Blégny. KBO
- Reihnard Löwenstein became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 321,476 loss in 2022 to € 126,477 loss in 2025.
Paid € 1,276 in corporate taxes since 2022.
On average € 54,200 of value added per employee in 2025.
A new publication or filing at LÖWENSTEIN MEDICAL BELGIUM? We notify you, reason included.
Follow LÖWENSTEIN MEDICAL BELGIUMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind LÖWENSTEIN MEDICAL BELGIUM are Johannes Wilhelmus Maria OUDE BREUIL and Reihnard Löwenstein. The shares are held by Löwenstein Medical Luxembourg SA.
Directors
According to the 2025 annual accounts
Johannes Wilhelmus Maria OUDE BREUIL
Director
since 2024
Reihnard Löwenstein
Director
since 2021
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Prés-Champs 25 box A
4671 Blégny
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.
All companies at this address →FAZ CONSULT
€ 300,000 revenue · 2025
FMM CONSULTING
€ 300,000 revenue · 2025
ONE-UP
€ 246,554 revenue · 2025
U-HOUSE
€ 82,797 revenue · 2025
U-POWER
€ 1.8 million revenue · 2023
+3 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0765.612.486
- VAT number
- BE 0765.612.486
- Registered office
- Rue Prés-Champs 25 bus A, 4671 Blégny
- Names & denominations
- LÖWENSTEIN MEDICAL BELGIUM
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 24 March 2021
- Peppol
- Active · Active since 6 Nov 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in andere machines en werktuigen, neg
Groothandel in andere machines en werktuigen, n.e.g.